Depression in older adults—often referred to as late-life depression (LLD)—is a silent crisis that affects millions worldwide. Unlike depression in younger populations, LLD comes with unique challenges: limited response to traditional antidepressants, poor tolerance to medication side effects, high rates of comorbidities (such as dementia or chronic pain), and an increased risk of treatment-resistant depression (TRD). For decades, clinicians and researchers have sought safer, more effective non-pharmaceutical interventions. Today, repetitive transcranial magnetic stimulation (rTMS) emerges as a promising solution, backed by growing scientific evidence. In this blog, we’ll break down key research findings on rTMS for geriatric depression, exploring its efficacy, safety, and how it’s reshaping care for older adults.
Why Traditional Treatments Fall Short for Older Adults with Depression
Older adults face distinct barriers to effective depression treatment. Antidepressant medications, the first-line option for many, often yield subpar results: studies show that up to 50% of older adults with depression don’t respond adequately to initial drug therapies. Worse, side effects like dizziness, fatigue, or cognitive fog can be debilitating for seniors, many of whom are already managing other health conditions or taking multiple medications. This has led to a critical need for non-invasive, well-tolerated alternatives—and rTMS fits the bill.
rTMS works by delivering painless magnetic pulses to specific regions of the brain (most commonly the dorsolateral prefrontal cortex, DLPFC), which are underactive in people with depression. Unlike electroconvulsive therapy (ECT), another non-pharmaceutical option, rTMS doesn’t require anesthesia and doesn’t cause memory loss—a major concern for older adults. But does it actually work for LLD? Let’s turn to the research.
Key Research Findings: rTMS Efficacy in Geriatric Depression
Over the past decade, multiple studies have validated rTMS as a safe and effective treatment for older adults with depression—especially those who haven’t responded to medications. Here’s what the data shows:
1. Bilateral rTMS Outperforms Unilateral Stimulation
One critical question in rTMS research is: Which stimulation approach works best for older adults? A 2019 study by Trevizol et al. published in the Journal of Affective Disorders shed light on this. The researchers recruited 43 adults aged 60 and older with treatment-resistant geriatric depression, assigning them to three groups: bilateral sequential rTMS (1Hz low-frequency stimulation on the right DLPFC + 10Hz high-frequency stimulation on the left DLPFC), unilateral high-frequency rTMS on the left DLPFC, or sham (placebo) stimulation. After six weeks of treatment, the results were striking: 40% of the bilateral rTMS group achieved remission (no longer meeting depression criteria), compared to 0% in the unilateral and sham groups. The bilateral group also showed significantly greater improvements in Hamilton Depression Rating Scale (HDRS) scores—an industry-standard measure of depression severity.
Why is bilateral stimulation more effective? Trevizol et al. (2019) suggest that age-related changes in the brain—such as prefrontal cortex atrophy and increased coil-to-cortex distance—may reduce the impact of unilateral stimulation. Bilateral stimulation targets both hemispheres, compensating for these age-related declines.
2. Higher Pulse Counts Boost Remission Rates
Treatment parameters—like the total number of magnetic pulses delivered—also play a key role in rTMS success. Two landmark trials led by Jorge et al. found a clear link between pulse count and remission rates in older adults (Jorge et al., 2008). In these studies, patients receiving 18,000 total pulses over the course of treatment had a remission rate of 27.3%, compared to just 13.3% in those receiving 12,000 pulses. Notably, both pulse counts are lower than the 90,000-pulse standard recommended by the FDA for younger adults—yet even these reduced doses showed meaningful benefits for seniors, with fewer side effects.
3. Combining rTMS with Antidepressants Enhances Efficacy
For older adults who are already taking antidepressants but still struggling with symptoms, adding rTMS can be a game-changer. A 2023 study by Wang et al. enrolled 120 middle-aged and older adults with depression, randomizing them to receive either escitalopram (a common antidepressant) plus rTMS or escitalopram plus sham stimulation (Wang et al., 2023). After eight weeks, the combination group had a total effective rate of 95.0%—far higher than the 80.0% rate in the medication-only group. The combination group also showed greater reductions in HDRS scores and improved quality of life.
4. rTMS Improves Cognition (and Is Safer Than ECT)
Cognitive impairment is a common comorbidity of geriatric depression, and many treatments fail to address this. However, rTMS offers a dual benefit: treating depression and boosting cognitive function. A 2022 study by Cappon et al. found that older adults who received rTMS (either alone or combined with medication) had significant improvements in Montreal Cognitive Assessment (MoCA) scores and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores—measures of memory, attention, and executive function (Cappon et al., 2022). Unlike ECT, which can cause temporary or permanent memory loss, rTMS showed no negative impact on cognition.
Cappon et al. also linked these cognitive improvements to changes in brain-derived neurotrophic factor (BDNF)—a protein that supports brain cell growth and function (Cappon et al., 2022). Patients in the rTMS group had significantly higher BDNF levels (36.00ng/ml) compared to those in the medication-only group (30.00ng/ml), suggesting a biological mechanism behind rTMS’s cognitive benefits.
Safety and Tolerability: A Big Win for Seniors
One of the most compelling aspects of rTMS for older adults is its safety profile. All four key studies—Trevizol et al. (2019), Jorge et al. (2008), Cappon et al. (2022), and Wang et al. (2023)—reported that rTMS was well-tolerated, with no serious adverse events. The most common side effects were mild scalp discomfort, headache, and temporary insomnia—all of which resolved on their own within days. Importantly, the rate of side effects was similar between rTMS (bilateral or unilateral) and sham stimulation, meaning the treatment itself didn’t add significant risk.
Dropout rates were also low (below 20% across all studies), indicating that older adults were willing to complete the full course of treatment—a key indicator of real-world feasibility.
What This Means for Older Adults with Depression
For seniors struggling with depression—especially those who haven’t found relief from medications—rTMS offers hope. The research is clear: bilateral rTMS (Trevizol et al., 2019), optimized pulse counts (Jorge et al., 2008), and combination with antidepressants (Wang et al., 2023) can significantly improve remission rates, reduce symptoms, and enhance cognitive function—all with minimal side effects.
Of course, rTMS isn’t a one-size-fits-all solution. As with any treatment, it’s important for older adults to work with a healthcare provider who specializes in geriatric mental health and rTMS. Providers can tailor the stimulation approach (bilateral vs. unilateral), adjust pulse counts, and coordinate with existing medication regimens to maximize benefits.
Future Directions in rTMS Research
While the current evidence is promising, there’s still work to be done to refine rTMS for geriatric depression. Researchers are focusing on three key areas:
- Large-scale, long-term studies: Most existing research (e.g., Trevizol et al., 2019; Wang et al., 2023) follows patients for 3–8 weeks. Future studies will need to track outcomes for 6 months or more to confirm rTMS’s long-term efficacy and safety.
- Standardized parameters: Currently, stimulation frequency, intensity, and pulse counts vary across studies (Cappon et al., 2022). Developing age-specific guidelines will help clinicians deliver consistent, effective care.
- Combination with other therapies: Researchers are exploring how rTMS pairs with cognitive-behavioral therapy (CBT) or lifestyle interventions (like exercise) to further improve outcomes for older adults.
Final Thoughts
Geriatric depression doesn’t have to be a life sentence. rTMS is a groundbreaking non-pharmaceutical treatment that addresses the unique challenges of LLD—offering efficacy, safety, and cognitive benefits that traditional treatments can’t match. Backed by rigorous scientific research from Trevizol et al. (2019), Jorge et al. (2008), Cappon et al. (2022), and Wang et al. (2023), rTMS is changing the way we care for older adults with depression, giving them the chance to live fuller, healthier lives.
If you or a loved one is an older adult struggling with depression—especially if medications haven’t worked—talk to your doctor about rTMS. It could be the solution you’ve been looking for.
References
- Trevizol, A. P., Goldberger, K. W., Mulsant, B. H., Rajji, T. K., Downar, J., Daskalakis, Z. J., & Blumberger, D. M. (2019). Bilateral sequential repetitive transcranial magnetic stimulation for treatment-resistant late-life depression: A randomized controlled trial. Journal of Affective Disorders, 251, 386–393. https://doi.org/10.1016/j.jad.2019.03.035
- Jorge, R. E., Moser, D. J., Acion, L., & Robinson, R. G. (2008). Treatment of vascular depression using repetitive transcranial magnetic stimulation. Archives of General Psychiatry, 65(3), 268–276. https://doi.org/10.1001/archgenpsychiatry.2007.45
- Cappon, D., den Boer, T., Jordan, C., Yu, W., Metzger, E., & Pascual-Leone, A. (2022). Transcranial Magnetic Stimulation (TMS) for Geriatric Depression. Ageing Research Reviews, 74, 101531. https://doi.org/10.1016/j.arr.2021.101531
- Wang, X., Fan, X., Zhang, L., Liu, X., & Ji, Z. (2023). Repetitive transcranial magnetic stimulation in the treatment of middle-aged and elderly major depressive disorder: A randomized controlled trial. Medicine (Baltimore), 102(35), e34841. https://doi.org/10.1097/MD.0000000000034841